IL1B and diabetes mellitus: We refer to this strategy of trading time for a reduction in inflammation severity as “Hours Exchanged Against (severity) Loss (HEAL).” Based on this HEAL hypothesis, obese patients without diabetes may derive a survival benefit from early IL-1β-targeted intervention during the initial stages of severe sepsis of cholangitis.